<div id="readability-page-1"><div><p>Johnson &amp; Johnson announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases were performed with zero fluoroscopy and 90% of patients achieved primary effectiveness at 12 months. OMNY-AF is a prospective, single-arm, multi-center clinical trial conducted across more than 40 sites in the U.S. and Australia.</p><p>The study pairs the OMNYPULSE Catheter, a 12 mm large-tip focal catheter featuring contact-force sensing and bipolar, biphasic pulse delivery with the TRUPULSE Generator. This integrated design combines precise mapping, controlled energy delivery and live feedback through the PF index on the CARTO 3 System. The OMNYPULSE Platform is not currently approved in any region of the world.</p><p>Alongside the OMNY-AF data, Johnson &amp; Johnson is highlighting new findings related to the VARIPULSE Platform. Data presented by Andrea Natale, M.D.2, and simultaneously published in JACC Clin Electrophysiology, by Moussa Mansour, M.D.3 examined the incidence of neurovascular events following the workflow enhancements and the introduction of an optimized irrigation flow rate. Notably, the platform sustained a low neurovascular event rate of 0.22% in 6,811 patients after implementation of both workflow enhancements and the updated irrigation rate.</p><p>Additional VARIPULSE Platform data presented at AF Symposium adds to the growing body of evidence underscoring the platform's consistent and favorable safety profile across a range of clinical and real-world settings, including: VARISURE Safety survey data presented by Christopher Porterfield, M.D.4: Early results from this physician survey on 850 procedures indicated low complication rates with a 1.9% rate of primary adverse events, a 0.2% incidence of neurovascular events and no reported cases of coronary spasm or death. Same-day discharge was achieved in 87.9% of patients. REAL AF registry analysis presented by Mohammad-Ali Jazayeri, M.D.5: Results from the REAL AF registry showed excellent acute safety outcomes of the VARIPULSE Catheter, with a low overall acute safety event rate of 0.5% with no neurovascular events, high rates of same-day discharge and no observed differences in safety outcomes across AFib classifications.</p><p>Irrigation Flow Optimization research presented by Fengwei Zou, M.D.6: Preclinical data demonstrated parity between the 4 mL/min and 30 mL/min irrigation rates in microbubble generation, hemolysis and lesion depth when using the VARIPULSE catheter, while confirming that higher irrigation significantly reduced electrode surface heating.</p></div></div>

标普全球医疗股指数 ETF - iShares

美国医药设备 ETF - iShares

医疗业 ETF - SPDR

强生

标普健康医疗设备 ETF - SPDR

基因改革 ETF - ARK

美国制药 ETF - iShares

医疗业 ETF - Vanguard

<p>强生在第 31 届年度心房颤动研讨会上展示了 OMNY-AF 研究的 12 个月试点数据，展示了用于治疗症状性阵发性心房颤动（AFib）的实验性 OMNYPULSE 平台。该研究报告在 30 名患者中实现了 100% 的急性手术成功率，且没有不良事件。此外，关于 VARIPULSE 平台的研究结果显示，在 6811 名患者中，神经血管事件发生率低至 0.22%，强调了其良好的安全性。该研究涉及美国和澳大利亚的 40 多个研究中心，但 OMNYPULSE 平台尚未获得全球批准</p>

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

marketscreener

强生公司在 2026 年 AF 研讨会上公布 OMNY-AF 试点研究的初步结果